Evaluation of the Role of Macrophage Migratory Inhibitory Factor (MIF) in mediating Stem Cell Analgesia in a Model of Orofacial Pain
评估巨噬细胞迁移抑制因子(MIF)在口面部疼痛模型中介导干细胞镇痛的作用
基本信息
- 批准号:10585412
- 负责人:
- 金额:$ 46.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-01 至 2027-12-31
- 项目状态:未结题
- 来源:
- 关键词:AMD3100Absence of pain sensationAcetaminophenAfferent NeuronsAnimalsAntibodiesApicalAttenuatedBehaviorBehavioral AssayCRISPR/Cas technologyCXCR4 ReceptorsCXCR4 geneCapsaicinCell LineCoculture TechniquesDataDegenerative polyarthritisDisease ProgressionEffectivenessElectrophysiology (science)EndodonticsEvaluationFemaleFosteringGoalsHomeHomingHumanImageIn VitroInfectionInjectionsKnock-outKnowledgeLigandsMacrophageMechanicsMediatingMedicalMesenchymal Stem CellsMigraineModelingMusNeuronsNociceptionNon-Steroidal Anti-Inflammatory AgentsOpioidOrofacial PainPainPathway interactionsPatientsPeriapical GranulomaPeriapical PeriodontitisPeripheralPersistent painPertussis ToxinProteinsRegulationResearchRodent ModelRoleRouteSex DifferencesSignal PathwaySignal TransductionSiteSystemTestingTherapeuticTissuesTooth structureToothacheTrigeminal SystemUp-Regulationantagonistantinociceptionattenuationcomparison controlconditioned place preferenceexperiencehuman stem cellsin vitro activityin vivoknock-downmalemechanical allodyniamicrobialmouse modelnon-opioid analgesicnovelorofacialpain behaviorpainful neuropathyperipheral painprogramspublic health relevancereceptorsecondary analysisside effectsmall hairpin RNAsmall moleculestem cellstongue papillavoltage
项目摘要
Abstract/Project Summary
The effectiveness and mechanisms of stem cell-induced analgesia in treating dental pain is unknown.
We demonstrate that i.v. injections of human Stem Cells of Apical Papilla (hSCAP) reverse apical periodontitis
(infection of a tooth; AP)-induced mechanical allodynia. Moreover, hSCAP primed to periapical granulomas
(peripheral sites of tooth infection) attenuate capsaicin (CAP)-evoked intracellular Ca2+ accumulation ([Ca2+]I)
from trigeminal (TG) neurons and this effect is inhibited by anti-human macrophage migratory inhibitory factor
(MIF)-antibody (Ab). Therefore, here, we will test the central hypothesis that apical periodontitis-induced
nociceptive behaviors is reversed by hSCAP-derived release of MIF that directly inhibits TG neuronal activity.
We propose the following aims to test the central hypothesis in male and female tissues:
Specific Aim 1 will test the hypothesis that hSCAP-derived MIF inhibits TG neuronal activities in vitro
and in vivo. We will use anti-human MIF-Ab to evaluate the effect of in vivo release of MIF by hSCAP on
mechanical allodynia as well as spontaneous nociception using conditioned placed preference (CPP). Next,
using CRISPR-Cas9, we will generate a hSCAP cell line with MIF knockout. This cell line will be used to test
the hypothesis that in vitro and in vivo hSCAP-derived MIF inhibits TG neurons and AP-induced pain
behaviors.
Specific Aim 2 will test the hypothesis that neuronal CXCR4 and CD74 receptors mediate MIF-induced
inhibition of TG neuronal activity in vitro and in vivo. MIF signals via the CXCR4 and CD74 receptors
(21-23) that are expressed on mouse TG neurons (Fig. 11). We will evaluate the role of CXCR4 using
AMD3100, a small molecule CXCR4 antagonist using in vitro Ca2+-imaging and in vivo behavioral assays.
Next, we conditionally delete CXCR4 from TG sensory neurons to evaluate the function of CXCR4 receptors
in vitro and in vivo. Next, will inject mice with AVV-shRNA against CD74 via an intraganglionic route to
assess the effect of neuronal CD74 receptor knockdown on in vivo nociceptive behaviors and as well as in
vitro Ca2+-imaging.
Specific Aim 3 will determine the signaling pathway/s activated by MIF that contribute inhibition of TG
neuronal activity. Signaling via CD74/CXCR4 receptor occurs via Gi/o proteins. We demonstrate that 1)
pretreatment with pertussis toxin (PTx) completely reverses hSCAP-induced attenuation of [Ca2+]I (Fig. 15);
and 2) MIF inhibits voltage gated Ca2+ currents (VGCaC; Fig 16) that is downstream of G activation. Using
electrophysiological approaches, we will determine MIF signaling by determining Gi versus G signaling,
type of VGCC inhibited, regulation of channels/receptors commonly known to mediate mechanical and
spontaneous behaviors and finally study alternative Gi/o-mediated pathways commonly known post-MIF
activation.
These studies have high medical significance as they define a novel ligand-receptor system for treating
infection-induced pain, possibly leading to new non-opioid analgesics. Importantly, the combined use of
human hSCAP in rodent models foster mechanistic research and increases translational significance.
RELEVANCE: These studies aim at studying new class of non-opioid analgesics for dental pain.
摘要/项目摘要
干细胞诱导的镇痛治疗牙齿疼痛的有效性和机制尚不清楚。
我们证明了i.v.对顶乳头(HSCAP)反向根尖牙周炎的人类干细胞注射
(牙齿感染; AP)诱导的机械性异常。此外,HSCAP启动至根尖的肉芽肿
(牙齿感染的外围部位)衰减辣椒素(CAP)诱发的细胞内Ca2+积累([CA2+] I)
抗人类巨噬细胞迁移抑制因子抑制三叉神经元(TG)神经元(TG)神经元
(MIF) - 抗体(AB)。因此,在这里,我们将测试中心牙周炎诱导的中心假设
HSCAP衍生的MIF释放直接抑制TG神经元活性的MIF释放可以逆转伤害性行为。
我们提出以下旨在检验男性和女性时间的中心假设:
特定目标1将检验以下假设:HSCAP衍生的MIF在体外抑制TG神经元活性
和体内。我们将使用抗人Mif-AB来评估HSCAP对MIF释放的效果
使用条件放置偏好(CPP)的机械异常性疾病以及赞助的nocetion。下一个,
使用CRISPR-CAS9,我们将与MIF敲除生成HSCAP单元线。该单元线将用于测试
体外和体内HSCAP衍生的MIF抑制TG神经元和AP诱导的疼痛的假设
行为。
特定目标2将检验以下假设:神经元CXCR4和CD74受体介导MIF诱导的假设
在体外和体内抑制TG神经元活性。 MIF信号通过CXCR4和CD74受体
(21-23)在小鼠TG神经元上表达(图11)。我们将使用CXCR4的角色使用
AMD3100,一种使用体外CA2+成像和体内行为测定的小分子CXCR4拮抗剂。
接下来,我们从TG感觉神经元中有条件删除CXCR4来评估CXCR4受体的功能
体外和体内。下一
评估神经元CD74受体敲低对体内伤害性行为的影响以及
体外Ca2+成像。
特定的目标3将确定由MIF激活的信号传导途径,从而抑制TG
神经元活性。通过CD74/CXCR4受体通过GI/O蛋白进行信号传导。我们证明了1)
用百日咳毒素(PTX)预处理完全逆转了[Ca2+] i的HSCAP诱导的衰减(图15);
2)MIF抑制G激活下游的电压门控Ca2+电流(VGCAC;图16)。使用
电生理方法,我们将通过确定GI与G信号传导来确定MIF信号传导,
抑制VGCC的类型,调节通道/受体通常已知会介导机械和
赞助行为,最后研究替代性GI/O介导的途径,通常已知的MIF
激活。
这些研究具有很高的医学意义,因为它们定义了一种用于治疗的新型配体受体系统
感染引起的疼痛,可能导致新的非阿片类镇痛药。重要的是,联合使用的
啮齿动物模型中的人类HSCAP促进了机械研究并增加了翻译意义。
相关性:这些研究旨在研究新的非阿片类镇痛药以解决牙齿疼痛。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nikita Ruparel其他文献
Nikita Ruparel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
An AI-based Multimodal Approach to Predict Pain in Postnatal Care Scenarios
基于人工智能的多模式方法来预测产后护理场景中的疼痛
- 批准号:
10546650 - 财政年份:2022
- 资助金额:
$ 46.38万 - 项目类别:
Peripherally Acting Analgesic for Osteoarthritis Pain
用于治疗骨关节炎疼痛的外周镇痛药
- 批准号:
10249564 - 财政年份:2021
- 资助金额:
$ 46.38万 - 项目类别:
Optimizing the use of ketamine to reduce chronic postsurgical pain
优化氯胺酮的使用以减少慢性术后疼痛
- 批准号:
10405697 - 财政年份:2021
- 资助金额:
$ 46.38万 - 项目类别:
Prescription After CesareanTrial - (PACT) MFMU Supplement
剖腹产试验后的处方 - (PACT) MFMU 补充
- 批准号:
10434255 - 财政年份:2021
- 资助金额:
$ 46.38万 - 项目类别:
Optimizing the use of ketamine to reduce chronic postsurgical pain
优化氯胺酮的使用以减少慢性术后疼痛
- 批准号:
10527397 - 财政年份:2021
- 资助金额:
$ 46.38万 - 项目类别: